GNBT - Generex Biotechnology Corporation

Other OTC - Other OTC Delayed Price. Currency in USD
1.7700
-0.0500 (-2.75%)
At close: 3:58PM EST
Stock chart is not supported by your current browser
Previous Close1.8200
Open1.7900
Bid0.00 x 0
Ask0.00 x 0
Day's Range1.5300 - 1.7900
52 Week Range0.0838 - 3.1000
Volume90,845
Avg. Volume283,573
Market Cap106.744M
Beta (3Y Monthly)-4.29
PE Ratio (TTM)3.63
EPS (TTM)0.49
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est6.00
Trade prices are not sourced from all markets
  • GlobeNewswireyesterday

    KALY – Kali-Extracts, Inc. Previews Pending Report On Cannabis Treatment For Lung Disease Study

    DALLAS, Feb. 21, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (KALY) (“KALY”) today published a second preview of a pending full report on their long-term, pilot study on the treatment of Chronic Obstructive Pulmonary Disease (COPD) in primates with cannabis extracts derived from Kali-Extracts patented cannabis extraction process.  The first preview was published on February 5, 2019.  The full report is expected within the next 2 weeks. The primate study adds to the Kali-Extracts in vitro genomics study, previously announced, to evaluate the impact of its pharmaceutical grade cannabis extracts in combination with other therapies on COPD patients.  The World Health Organization estimates 65 million people worldwide are afflicted with moderate to severe COPD and GlobalData forecasts that the COPD treatment market will reach $14.1 billion by 2025.

  • GlobeNewswire3 days ago

    Generex Biotechnology Subsidiary Regentys Corporation Receives Approval of Japanese Patent for Extracellular Matrix Hydrogel (Regentys ECMH™)

    MIRAMAR, FL, Feb. 19, 2019 -- via NEWMEDIAWIRE -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to.

  • GlobeNewswire7 days ago

    Generex Biotechnology Announces Investor Conference Call Agenda; Tuesday, February 26, at 11:00 A.M. Eastern

    MIRAMAR, FL, Feb. 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote), today announced an agenda for the investor conference call to be presented Tuesday, February 26, at 11:00 AM. Eastern time. Joseph Moscato, President & Chief Executive Officer of Generex will provide a February update on the progress and status of the company’s strategic plans and operations. Mr. Moscato will provide new information on current and planned acquisitions of products and businesses that bolster and expand the capabilities and service offerings of the NuGenerex family of subsidiary companies, continuing the Generex mission to provide integrated solutions for patients and the healthcare community.

  • GlobeNewswire10 days ago

    Generex Announces Appointment of Marshal Schictman, Esq. as Executive Vice President General Counsel and Corporate SEC Attorney

    MIRAMAR, FL, Feb. 12, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Generex Biotechnology Corporation (GNBT) is pleased to announce that Marshal Schictman, Esq. Mr. Schictman has practiced law for over 16 years, with wide-ranging expertise in the areas of corporate, securities, and finance law, primarily in the areas of capital markets and securities trading.

  • GlobeNewswire17 days ago

    KALY – Kali-Extracts, Inc. Publishes Cannabis Extract Lung Disease Treatment Study Preview

    DALLAS, Feb. 05, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (KALY) (“KALY”) today published a preview of the recently announced long-term, pilot study on the treatment of Chronic Obstructive Pulmonary Disease (COPD) in primates with cannabis extracts derived from Kali-Extracts patented cannabis extraction process.  The study adds to the Kali-Extracts in vitro genomics study, previously announced, to evaluate the impact of its pharmaceutical grade cannabis extracts in combination with other therapies on COPD patients.  The World Health Organization estimates 65 million people worldwide are afflicted with moderate to severe COPD and GlobalData forecasts that the COPD treatment market will reach $14.1 billion by 2025.

  • GlobeNewswire18 days ago

    Generex Biotechnology Responds to Demand for Payment

    MIRAMAR, FL, Feb. 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) provided a response to the demand for payment from Alpha Capital Anstalt. As reported in our 8-K filed on January 31, 2019, Generex (GNBT) received a demand, on January 25, 2019, from Alpha Capital for immediate repayment of Generex’s Note Due October 26, 2019 (“Note”), coupled with an intent to sue Generex if payment was not made. Although Generex has not defaulted in any payment, Alpha Capital called a default under the Note based on terms stating that Generex must up-list to the NASDAQ market within a specified time.  If litigation ensues, Generex intends to assert affirmative defenses that Alpha took aggressive actions to intentionally harm Generex as the company executed on it plan to up-list to NASDAQ, intentionally frustrating key elements necessary for the up-listing.  CEO Joseph Moscato personally guaranteed the instrument with his own personal shares.

  • ACCESSWIRE21 days ago

    LD Micro Welcomes Nearly 1,000 Companies to the LD Micro Index

    LOS ANGELES, CA / ACCESSWIRE / February 1, 2019 / LD Micro is pleased to announce that the LD Micro Index is being reconstituted as of February 1, 2019. Again. We have always held the belief that our industry ...

  • PR Newswire21 days ago

    KALY - Kali-Extracts, Inc. Announces Cannabis Extract COPD Primate Treatment Study Research Report Preview

    DALLAS , Feb. 1, 2019 /PRNewswire/ -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) ("KALY") today announced a preview presentation scheduled for next week, on Tuesday, ...

  • GlobeNewswire23 days ago

    KALY Releases Update Highlighting Potential In $14 Billion COPD Treatment Market and Additional Pharmaceutical Markets

    DALLAS, Jan. 30, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (KALY) (“KALY”) today released a corporate update that includes the latest on KALY’s developments with Puration, Inc, (PURA) (“PURA”) and Generex Biotechnology, Inc. (GNBT), the company’s research on treatments for Chronic Obstructive Pulmonary Disease (COPD), and other updates.

  • GlobeNewswire24 days ago

    Generex Biotechnology Announces Investor Conference Call Scheduled for February 26, 2019

    MIRAMAR, FL, Jan. 29, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Generex Biotechnology Corporation (www.generex.com) (GNBT), today announced that it will hold a conference call on Tuesday, February 26th at 11:00 am to update investors on the completed share dividend for NuGenerex Immuno-Oncology (NGIO), as well as detailed plans for listing the shares on a public exchange. Generex will also provide details on the acquisition and integration of Fuse Medical, Pantheon Medical, and MediSource Partners, three companies that manufacture and distribute surgical and biologic products for orthopedic surgeons and podiatrists, many of which are members of the Nugenerex Distribution Solutions MSO. Joseph Moscato, Generex President & Chief Executive Officer, will discuss the company’s financing plans related to these and other, soon to be announced acquisitions that will enable Generex Biotechnology to augment the company’s product portfolio, further grow its provider networks, and expand its ancillary healthcare service offerings.

  • GlobeNewswire28 days ago

    KALY - Kali-Extracts COPD Research Targeting $14 Billion Treatment Market To Be Featured In Online Corporate Update Next Week

    DALLAS, Jan. 25, 2019 -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC: KALY) (“KALY”) today announced an online corporate update scheduled.

  • GlobeNewswire28 days ago

    Generex Launches DME-IQ, the “Smart Solution” for In-Office Management of Durable Medical Equipment

    MIRAMAR, FL, Jan. 25, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Generex Biotechnology Corporation (www.generex.com) (GNBT)  (http://www.otcmarkets.com/stock/GNBT/quote) announced today that its wholly-owned subsidiary NuGenerex Distribution Solutions 2, LLC (NDS) has launched DME-IQ, a novel service for physicians who manage in-office distribution of durable medical equipment (DME). DME-IQ supports the development and management of compliant and profitable in-office DME programs.  DME-IQ focuses on several key areas, which include negotiating on behalf of the physicians with key vendors to decrease the Cost of Goods (COG’s), increasing insurance collections by providing oversight of the coding during the billing process, providing the necessary personnel to manage the appeals processes, and ensuring compliance with state and federal regulations.

  • GlobeNewswire29 days ago

    Generex Subsidiary NuGenerex Diagnostics Announces CE-Mark Certification for its Rapid Point-of-Care Express II Syphilis Treponemal Assay

    Commercialization of medical devices in the European Union requires meeting the regulatory guidelines of the European Medical Devices Directive (MDD) and fulfillment of those requirements allows a device to carry the “CE-Mark” as verification of its diagnostic authenticity. After completing rigorous test validation and submission of an application to the European Union, NuGenerex Diagnostics is pleased to announce that the CE Mark Certification for its The Express II Syphilis Treponemal Assay has been granted.

  • GlobeNewswirelast month

    Generex Announces REVISED Record Date for NuGenerex Immuno-Oncology Stock Dividend

    MIRAMAR, FL , Jan. 23, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced that it has REVISED the record date for the previously announced dividend to Generex shareholders of shares in our wholly-owned subsidiary NuGenerex Immuno-Oncology (formerly Antigen Express). The Record Date for the determination of the holders of the Company’s common stock entitled to participate in the dividend will now be January 30, 2019.  The dividend Payment Date remains February 25, 2019. The Company believes that the ex-dividend date will be Monday, January 28, 2019 by application of FINRA Uniform Practice Code rules which provide ex-dividend date for dividends of less than 25 percent of the value a company’s common stock is the second business day prior to the record date.

  • GlobeNewswirelast month

    Generex Biotechnology Provides 2018 Year-End Summary & 2019 Plans

    MIRAMAR, FL, Jan. 22, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is happy to provide the investment community with a review of the many accomplishments achieved in 2018, with a vision for growth in 2019 by Generex CEO Joseph Moscato. At the end of 2017, Generex formed a new, wholly-owned subsidiary, NuGenerex Distribution Solutions, LLC (NDS), completing the initial organizational restructuring of the company. In January 2018, NDS acquired Empire State Pharmacy LLC in New York and Grainland Pharmacy LLC in Kansas, commencing the Company’s strategic plans to establish itself as a presence in the U.S. direct-to-consumer pharmaceuticals business.

  • GlobeNewswirelast month

    Kali-Extracts and Puration Announce First Ever 25 mg CBD Extract Formulation For Beverage Infusion

    DALLAS, Jan. 17, 2019 (GLOBE NEWSWIRE) -- via OTC PR WIRE -- Kali-Extracts, Inc. (Kali, Inc. dba/Kali-Extracts, Inc.) (KALY) (“KALY”) and Puration, Inc, (PURA) (“PURA”) today announced a new 25 mg CBD Extract formulation for beverage infusion.  KALY owns and manages a patented cannabis extraction process.  PURA has licensed the KALY patent for beverage infusion.  PURA currently produces EVERx CBD Sports Water infused with 10 mg of CBD.  Together KALY and PURA are designing a new private labeled CBD infused beverage for Generex Biotechnology, Inc. (GNBT).

  • GlobeNewswirelast month

    Generex Announces Record & Payment Dates for NuGenerex Immuno-Oncology Stock Dividend

    MIRAMAR, FL, Jan. 16, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is pleased to announce that the company will dividend Generex shareholders with shares in our wholly-owned subsidiary NuGenerex Immuno-Oncology (formerly Antigen Express), with the ultimate plan to spin out the company on a public exchange. The dividend will be structured for Generex shareholders to receive 1 share of NuGenerex Immuno-Oncology for every 4 shares of Generex Biotechnology with the Record Date of Thursday, January 17, 2019, and a Payment Date of Monday, February 25, 2019. The stock dividend will result in the issuance of 1 share in NuGenerex Immuno-Oncology for every 4 shares of Generex Biotechnology common stock owned.

  • Business Wirelast month

    Generex Biotechnology Announces Investor Conference Call Agenda Wednesday, January 16, at 4:00 p.m. Eastern

    Generex Biotechnology Corporation (www.generex.com) (GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced an agenda for the investor conference call to be presented today, Wednesday January 16, at 4:00 p.m. Eastern time. Joseph Moscato, Chief Executive Officer of Generex will outline the company’s strategic and financial plans, including details on financing transactions pertaining to the previously reported acquisitions of the Veneto Group assets and Olaregen.

  • GlobeNewswirelast month

    Generex Announces Investor Conference Call-in Details; Management to Provide Update on Initiatives & Strategic Plans

    Joseph Moscato, Generex President & Chief Executive Officer, will discuss the company’s financing plans related to the acquisitions, as well as the strategic focus of Generex for 2019 and beyond. Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

  • Business Wirelast month

    Generex Biotechnology Subsidiary Olaregen Therapeutix Inc. Plans Launch of FDA Cleared Excellagen® Wound Conforming Gel Matrix with Three Dosage Options

    Generex Biotechnology Corporation (GNBT) is pleased to announce that Olaregen Therapeutix Inc., a subsidiary of Generex Biotechnology will launch three doses of FDA 510K-Cleared Excellagen, the company’s wound conforming gel matrix that is designated as a Cellular & Tissue Based Product or CTP for wound healing. The 0.5 cc and a 0.8 cc syringes will be utilized to treat smaller wounds such as diabetic foot ulcers, venous stasis ulcers, and pressure ulcers, and in patients who have undergone MOHs surgery for removal of cancerous tissue.

  • Business Wirelast month

    Generex Biotechnology Announces Acquisition of Surgical Supply and Distribution Company

    Generex Biotechnology Corporation (GNBT) is pleased to announce that the company has entered into a letter of intent (LOI) to acquire Medisource Partners, an FDA-registered distributor of medical and surgical products including bone grafts and biologics from a range of surgical product manufacturers. Under the terms of the deal, Generex will acquire all of the assets of Medisource including business operations, accounts receivable and inventory, contracts, and real estate, on a debt free basis, for One Million Dollars ($1,000,000) worth of Generex (GNBT) stock, plus additional cash and stock consideration for achieving certain sales and profit projections.

  • Business Wirelast month

    Generex Biotechnology Announces Investor Conference Call; Management to Provide Update on Acquisitions, Financing Initiatives & Strategic Plans

    Generex Biotechnology Corporation (www.generex.com) (GNBT) today announced that it will hold an investor conference call on Wednesday, January 16th, at 4:00 p.m. to update investors on the previously announced and pending acquisitions that offer significant value to the Generex parent company. Joseph Moscato, Generex President & Chief Executive Officer, will discuss the company’s financing plans related to the acquisitions, as well as the strategic focus of Generex for 2019 and beyond.

  • Business Wirelast month

    Generex Biotechnology Announces Acquisition of Surgical Device Manufacturer

    Generex Biotechnology Corporation (GNBT) is pleased to announce that the company has entered into a letter of intent (LOI) to acquire Pantheon Medical – Foot & Ankle, a manufacturer of specialty orthopedic surgery products and tools. Under the terms of the deal, Generex will acquire all of the assets of Pantheon Medical including business operations, accounts receivable and inventory, contracts, and an FDA letter related to balanced plating system, on a debt free basis, for One Million Four Hundred Thousand Dollars ($1,400,000) worth of Generex (GNBT) stock, plus additional cash and stock consideration upon achieving certain sales and profit goals.

  • GlobeNewswirelast month

    Generex Biotechnology Completes Acquisition of Olaregen Therapeutix Inc.

    - Closes transaction to complete 51% acquisition of Olaregen Therapeutix - Plans Commercial Launch of FDA-cleared Excellagen® MIRAMAR, Fla., Jan. 08, 2019 -- via OTC PR WIRE.